Schering settles dispute
|
|
August 13, 2001: 7:46 p.m. ET
Schering-Plough, Hoffman-La Roche agree to cross license hepatitis drug patents
|
NEW YORK (CNNfn) - Schering-Plough Corp. said Monday it has come to an agreement with Swiss company Hoffmann-La Roche Ltd., settling patent disputes over hepatitis treatments.
The two companies will seek dismissals of current patent lawsuits and will cross license all patents to their pegylated alpha interferon products Peg-Intron and Pegasys. They will also license patents to combinations of those drugs with ribavirin.
Financial terms of the deal were not disclosed and it is subject to the dismissal of the lawsuits.
Last week Schering-Plough (SGP: Research, Estimates) received approval for a new combination of its Peg-Intron treatment and its Rebetol capsules for treatment of chronic hepatitis C in patients with compensated liver disease.
|
|
|
|
|
|